Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fang Cai

Showing results (401-410 of 404) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 404 results.
Eclinicalmedicine|April 27, 2022
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Ivan O Rosas, Norbert Bräu, Michael Waters, et al.
World Journal of Psychiatry|November 20, 2024
Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophreniaBao-Yan Xu, Kun Jin, Hai-Shan Wu, et al.
Iscience|October 9, 2023
A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signalingJason A Hackney, Haridha Shivram, Jason Vander Heiden, et al.
Plos Genetics|November 3, 2022
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics InitiativeGuillaume Butler-Laporte, Gundula Povysil, Jack A Kosmicki, et al.
Pageof 41

Showing results (401-410 of 404) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 404 results.
Eclinicalmedicine|April 27, 2022
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Ivan O Rosas, Norbert Bräu, Michael Waters, et al.
World Journal of Psychiatry|November 20, 2024
Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophreniaBao-Yan Xu, Kun Jin, Hai-Shan Wu, et al.
Iscience|October 9, 2023
A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signalingJason A Hackney, Haridha Shivram, Jason Vander Heiden, et al.
Plos Genetics|November 3, 2022
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics InitiativeGuillaume Butler-Laporte, Gundula Povysil, Jack A Kosmicki, et al.
Pageof 41